抗PD-1癌症免疫疗法通过微质激活诱导中枢神经系统免疫相关的不良事件
Janaki Manoja Vinnakota1,2, Rachael C Adams1,3,4, Dimitrios Athanassopoulos1
1Department of Medicine I-Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Science translational medicine
|June 12, 2024
概括
抗PD-1免疫疗法可以触发中枢神经系统免疫相关不良事件 (CNS-irAEs). 这项研究揭示了微质细胞通过脏氨酸激酶 (Syk) 调解这些效应,提供了潜在的治疗点.
科学领域:
- 神经免疫学 神经免疫学
- 癌症免疫疗法癌症免疫疗法
- 在瘤学瘤学.
背景情况:
- 抗PD-1免疫疗法是一种重要的癌症治疗方法.
- 中枢神经系统免疫相关不良事件 (CNS-irAEs) 是已知的并发症.
- 微质在中枢神经系统-irAEs中的特定作用仍然不太清楚.
研究的目的:
- 调查微质在抗PD-1免疫疗法诱导的中枢神经系统irrAEs中的作用.
- 为了确定微质介导的中枢神经系统-irAEs背后的分子机制.
- 探索针对微质激活的潜在治疗策略.
主要方法:
- 使用抗PD-1治疗的小鼠模型.
- 进行单细胞RNA测序和蛋白质组学.
- 使用成像质细胞计分析了人类患者的中枢神经系统组织.
- 研究了腺氨酸激酶 (Syk) 抑制的作用.
主要成果:
- 抗PD-1治疗激活了小质细胞,并诱导了小鼠的神经认知缺陷,独立于适应性免疫.
- 微质通过抗体相互作用直接调解中枢神经系统-irAEs.
- Syk被确定为激活微质中的关键调解者.
- 抑制Syk可以改善神经认知缺陷和微质激活,而不会影响抗瘤效果.
- 人类患者的数据显示,抗PD-1治疗后微质激活标志物增加.
结论:
- 微质在抗PD-1诱导的中枢神经系统-irAEs中发挥着关键的,促进疾病的作用.
- 微质中的Syk信号是这些神经毒性影响的关键驱动因素.
- 准微质中的Syk是一种有希望的治疗途径,可以在抗PD-1免疫疗法期间减轻中枢神经系统-irAEs.
相关概念视频
Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159


